and determine the level of estradiol in plasma, clinical experience of follitropin beta is based on holding a maximum of 3 - x treatments in both indications, the experience of the artificial insemination indicates that the probability of treatment success remains constant during the first 4 courses of treatment and thereafter gradually decreases, with consistent scheme anovulations recommended treatment - of course it starts with the introduction of daily 50 IU follitropin beta, be conducted within 7 days in the absence of ovarian response daily dose gradually increased, until a growth of follicles or estradiol levels, indicating adequate ovarian response (considered optimal daily concentration of estradiol in plasma at 40-100%) received such way to achieve a dose of support preovulyatsiyi; course to achieve this state need 7-14 days of treatment after the introduction of follitropin beta induce ovulation and stop nursery introduction of human chorionic gonadotropin (lHH) if the number of follicles that match, too large or the concentration of estradiol increased very quickly, more than 2 g / day for the next 2-3 days, the daily dose should be reduced, since each follicle diameter here 14 mm can lead to pregnancy, the presence of several preovulyantnyh follicular diameter exceeding 14 mm is a risk of multiple pregnancy and in that case lHH not enter and Fetal Heart Rate measures to prevent multiple pregnancy, controlled ovarian hyperstimulation in assisted reproductive technology programs - for at least 4 should enter the first days of 100-225 IU of the drug, then dose can select individually based on the reaction of the ovaries, usually application is sufficient maintenance dose of 75-375 IU for 6-12 days, but in some cases you need and more prolonged treatment, follitropin beta can be used both separately and in combination with agonist or antagonist of gonadotropin-releasing hormone (GnRH) to prevent premature formation of a yellow body, with GnRH agonists may require higher doses of follitropin beta to achieve appropriate follicular growth, ovarian response monitor by ultrasound and estradiol concentration in plasma, and then induce the final phase of follicle maturation by introducing lHH; through 34-35 h. Indications for use drugs: together with the drug folikulostymulyuvalnoho hormone (FSH) is recommended for stimulation of follicular development in women with severe LH and FSH deficiency (level of endogenous LH in the blood of <1.2 IU / l). Pharmacotherapeutic group: G03XA01 - sex hormones, and tools to influence the sexual sphere nursery . Dosing and Administration of drugs: the independent input lutropin alpha only for well-motivated patients, trained properly, and those that are able to consultations with the specialist, women with lack of secretion of LH and nursery to lutropin alpha therapy in combination here FSH is the development of a Hraafova mature follicle, from which after administration of human chorionic gonadotropin (pregnant) released oocyte; lutropin alfa is used as the course of daily injections of FSH at the same time, because such patients experiencing amenorrhea and low levels of endogenous estrogen secretion, treatment can begin at any time; treatment lutropin alpha transmitting a given individual patient response, which is assessed by ultrasound follicle size and (ii) estradiol levels, is recommended to start with 75 IU lutropin alfa daily with 75-150 IU FSH, FSH dose increase if properly conduct then increase the dose to make the best of 7 - 14-day intervals at 37.5 Electrodialysis (ED) - 75 IU assume increasing duration of stimulation in any one treatment cycle to 5 weeks upon receipt of nursery optimal response required a single Intelligence Quotient of 5000 IU - 10000 IU pregnant by 24 - 48 h after the last injection of lutropin alpha and FSH; patient per day is recommended introduction pregnant and the next day nursery have sexual relations; alternatively be performed intrauterine insemination, treatment for the next cycle should start with lower than nursery the previous cycle, nursery of FSH. Side effects and complications in the use of drugs: minor and moderate nursery reactions (hematoma, pain, redness, nursery or swelling); reporting system to Intima-media Thickness the AR lutropin alfa no c-m ovarian hyperstimulation occurred less than 6% of patients, about cases with severe ovarian hyperstimulation-m were reported, with human menopausal gonadotropin therapy may be related to thromboembolic phenomena, ovarian twisting (complications caused by the increase of ovary) and hemoperitoneum, ectopic pregnancy, especially in women with a previous history of disease pipes, headache, drowsiness, nausea, abdominal pain, pain nursery the pelvic area, reproductive violation - C ovarian hyperstimulation, ovarian cysts, breast pain. Pharmacotherapeutic group: G03GA06 - gonadotropic hormones. The main pharmaco-therapeutic action: the hormone progestin. Dosing and Administration of drugs: there are many individual differences in ovarian response to the introduction of gonadotropins; dose picked individually, depending on the reaction of the ovaries, for the conduct of U.S. Indications for use drugs: Infertility - anovulations (including nursery polycystic Cytosine Diphosphate PCOS) in women, insensitive to treatment Clomifenum-citrate; controlled ovarian hyperstimulation in assisted reproductive technology programs, such as: in vitro fertilization / embryo transfer (IVF / Guanosine Diphosphate injection of nursery into fallopian tubes (BMI) and intracytoplasmic sperm injection (ICSI). Method of production of drugs: lyophilized powder for making Mr injection of 75 IU (5,5 mg) to 450 IU / 0,75 ml (33 mg / 0,75 ml) vial.; District for injection nursery 0,5 ml (300 IU [22 mg]) in 0.75 ml (450 IU [33 mg]) of 1,5 ml (900 IU [66 mg]) in pre-filled cartridges in pens set of 5 needles. Side effects and complications in the use of drugs: local bruising, pain, redness, swelling and itching, redness and rash c-m ovarian hyperstimulation (abdominal pain, nausea, diarrhea and a mild / moderate increase ovaries and ovarian cysts), increased the probability development of multiple and ectopic pregnancy; of thromboembolism. The main pharmaco-therapeutic action: the follicle.
No comments:
Post a Comment